Targeted Therapies for Patients With Ovarian Cancer Who Have BRCA-Mutated Tumors
January 26th 2018Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.